260 related articles for article (PubMed ID: 27379982)
21. Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease.
Chan E; Stohr BA; Butler RS; Cox RM; Myles JL; Nguyen JK; Przybycin CG; Reynolds JP; Williamson SR; McKenney JK
Am J Surg Pathol; 2022 Mar; 46(3):392-403. PubMed ID: 34881751
[TBL] [Abstract][Full Text] [Related]
22. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.
Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; St-Hilaire PA; Tian Z; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
World J Urol; 2021 Feb; 39(2):461-472. PubMed ID: 32253579
[TBL] [Abstract][Full Text] [Related]
23. Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.
Liu K; Ren Y; Pang L; Qi Y; Jia W; Tao L; Hu Z; Zhao J; Zhang H; Li L; Yue H; Han J; Liang W; Hu J; Zou H; Yuan X; Li F
Int J Clin Exp Pathol; 2015; 8(7):8311-35. PubMed ID: 26339402
[TBL] [Abstract][Full Text] [Related]
24. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
[TBL] [Abstract][Full Text] [Related]
25. Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma.
Khella HW; Scorilas A; Mozes R; Mirham L; Lianidou E; Krylov SN; Lee JY; Ordon M; Stewart R; Jewett MA; Yousef GM
Am J Pathol; 2015 Mar; 185(3):693-703. PubMed ID: 25572155
[TBL] [Abstract][Full Text] [Related]
26. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis.
Uhlman DL; Nguyen P; Manivel JC; Zhang G; Hagen K; Fraley E; Aeppli D; Niehans GA
Clin Cancer Res; 1995 Aug; 1(8):913-20. PubMed ID: 9816062
[TBL] [Abstract][Full Text] [Related]
28. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.
Saeednejad Zanjani L; Madjd Z; Abolhasani M; Andersson Y; Rasti A; Shariftabrizi A; Asgari M
Exp Mol Pathol; 2017 Oct; 103(2):218-228. PubMed ID: 29050853
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
[TBL] [Abstract][Full Text] [Related]
30. High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis.
Yang C; Shuch B; Kluger H; Humphrey PA; Adeniran AJ
Am J Surg Pathol; 2020 May; 44(5):582-593. PubMed ID: 32101890
[TBL] [Abstract][Full Text] [Related]
31. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
[TBL] [Abstract][Full Text] [Related]
32. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters.
Tsai WC; Sheu LF; Nieh S; Yu CP; Sun GH; Lin YF; Chen A; Jin JS
World J Urol; 2007 Mar; 25(1):73-80. PubMed ID: 17021824
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality.
Mejean A; Hopirtean V; Bazin JP; Larousserie F; Benoit H; Chrétien Y; Thiounn N; Dufour B
J Urol; 2003 Sep; 170(3):764-7. PubMed ID: 12913693
[TBL] [Abstract][Full Text] [Related]
34. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
35. [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
Waalkes S; Roos FC; Eggers H; Schumacher S; Janssen M; Wegener G; Thüroff JW; Hofmann R; Schrader M; Kuczyk MA; Schrader AJ;
Urologe A; 2011 Sep; 50(9):1125-9. PubMed ID: 21845424
[TBL] [Abstract][Full Text] [Related]
36. Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis.
He Z; Sun M; Ke Y; Lin R; Xiao Y; Zhou S; Zhao H; Wang Y; Zhou F; Zhou Y
Oncotarget; 2017 Apr; 8(17):27904-27914. PubMed ID: 28427189
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
Naffrichoux J; Poupin P; Pouillot W; Linassier C; Rioux-Leclercq N; De Vries-Brilland M; Mourey L; Laguerre B; Oudard S; Gross-Goupil M; Mousset C; Gravis G; Rolland F; Moise L; Emambux S; Vassal C; Zanetta S; Penel N; Albiges L; Fromont G; Cancel M
Eur J Cancer; 2024 Jul; 205():114121. PubMed ID: 38749111
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma.
Sandlund J; Ljungberg B; Wikström P; Grankvist K; Lindh G; Rasmuson T
Acta Oncol; 2009; 48(6):909-14. PubMed ID: 19322701
[TBL] [Abstract][Full Text] [Related]
39. Distribution of subtypes of metastatic renal-cell carcinoma: correlating findings of fine-needle aspiration biopsy and surgical pathology.
Mai KT; Alhalouly T; Lamba M; Yazdi HM; Stinson WA
Diagn Cytopathol; 2003 Feb; 28(2):66-70. PubMed ID: 12561022
[TBL] [Abstract][Full Text] [Related]
40. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
Zhao H; Leppert JT; Peehl DM
PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
